A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014
Open accessPublished version of a preprint
The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Abstract
Purpose: To estimate the maximum tolerated dose (MTD) for continuous oral administration of the γ-secretase inhibitor PF-03084014, determine the recommended phase II dose (RP2D), and evaluate safety and preliminary activity in patients with advanced solid tumors. Experimental Design: This open-label, phase I study consisted of a dose-finding portion based on a 3+3 design, followed by an expansion cohort. PF-03084014 was administered orally, twice daily (BID) for 21 continuous days. Tested doses ranged from 20 to 330 mg BID. In the expansion cohort, patients were to receive the estimated MTD or a lower dose of PF-03084014. Results: A total of 64 patients received treatment. The MTD was estimated to be 220 mg BID. The RP2D was determined to be 150 mg BID, based on the better safety profile versus the 220-mg BID dose, given comparable NOTCH-related target inhibition. The most common treatment-related adverse events were diarrhea, nausea, fatigue, hypophosphatemia, vomiting, rash, and decreased appetite, which were generally mild to moderate in severity. One patient with advanced thyroid cancer had a complete response, and five of seven response-evaluable patients with desmoid tumor achieved a partial response (71.4% objective response rate). Tumor responses were mostly durable, ranging from 1.74+ to 24+ months. PF-03084014 demonstrated a generally dose-dependent pharmacokinetic profile at doses ranging from 20 to 330 mg BID. Consistent downmodulation of NOTCH-related HES4 gene expression was observed in peripheral blood from all evaluable patients. Conclusion: Further development of PF-03084014 for the treatment of patients with advanced solid tumors is warranted and currently under evaluation. Clin Cancer Res; 21(1); 60–67. ©2014 AACR. See related commentary by Hughes et al., p. 7
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inhibiting γ‐secretase using small molecules like PF‐03084014 and BMS‐906024 has shown promising results in triple‐negative breast cancer, desmoid tumors and pancreatic ductal adenocarcinoma, and related phase II and III trials are currently underway [150, 151, 152, 153].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism
Kopan, R., & Ilagan, M. X. G. (2009) · Cell · doi:10.1016/j.cell.2009.03.045 · Cited by 3,643
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, C., Chang, K., Li, R. J., Fakhry, C., Xie, T.-X., Zhang, J., Wang, J., et al. (2011) · Science · doi:10.1126/science.1206923 · Cited by 1,697
A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease
Doody, R. S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1210951 · Cited by 1,224
Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways
Takebe, N., Harris, P. J., Warren, R. Q., & Ivy, S. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.196 · Cited by 992
Loss-of-function mutations in Notch receptors in cutaneous and lung squamous cell carcinoma
Wang, N. J., Sanborn, Z., Arnett, K. L., Bayston, L. J., Liao, W., Proby, C. M., Leigh, I. M., Collisson, E. A., Gordon, P. B., Jakkula, L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114669108 · Cited by 462
Targeting Notch to Target Cancer Stem Cells
Pannuti, A., Foreman, K., Rizzo, P., Osipo, C., Golde, T., Osborne, B., & Miele, L. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2823 · Cited by 450
Notch Signaling, γ-Secretase Inhibitors, and Cancer Therapy
Shih, I.-M., & Wang, T.-L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3958 · Cited by 421
Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer
Robinson, D. R., Kalyana-Sundaram, S., Wu, Y.-M., Shankar, S., Cao, X., Ateeq, B., Asangani, I. A., Iyer, M., Maher, C. A., Grasso, C. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2580 · Cited by 340
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy
McAuliffe, S. M., Morgan, S. L., Wyant, G. A., Tran, L. T., Muto, K. W., Chen, Y. S., Chin, K. T., Partridge, J. C., Poole, B. B., Cheng, K.-H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1206400109 · Cited by 328
Cited by
Targeting cancer stem cell pathways for cancer therapy
Yang, L., Shi, P., Zhao, G., Xu, J., Peng, W., Zhang, J., Zhang, G., Wang, X., Dong, Z., Chen, F., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0110-5 · Cited by 1,906
Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update
Takebe, N., Miele, L., Harris, P. J., Jeong, W., Bando, H., Kahn, M., Yang, S. X., & Ivy, S. P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.61 · Cited by 1,298
Notch signaling pathway: architecture, disease, and therapeutics
Zhou, B., Lin, W., Long, Y., Yang, Y., Zhang, H., Wu, K., & Chu, Q. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00934-y · Cited by 1,114
Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors
Krishnamurthy, N., & Kurzrock, R. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.002 · Cited by 1,026
The great escape: tumour cell plasticity in resistance to targeted therapy
Boumahdi, S., & de Sauvage, F. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0044-1 · Cited by 761
Metadata
- Authors
- Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., McLachlan, K. R., Kern, K. A., & LoRusso, P. M.
- Affiliations
- University of Colorado Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Pfizer (United States) (US)
- 4Pfizer Oncology, Milan, Italy.
- The Barbara Ann Karmanos Cancer Institute (US)
- Corresponding author
- Messersmith, Wells A.
- ORCID
- Venue
- Clinical Cancer Research
- Published
- 2015-01-01
- Volume
- 21
- Issue
- 1
- Pages
- 60-67
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2109541355
- Cited by
- 218
- References
- 31
- Citations by year
- 2026: 4 · 2025: 11 · 2024: 16 · 2023: 25 · 2022: 25 · 2021: 16 · 2020: 19 · 2019: 18 · 2018: 20 · 2017: 24 · 2016: 22 · 2015: 15
- FWCI
- 13.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- PF-03084014, gamma-secretase inhibitors, Notch signaling, advanced solid tumors, maximum tolerated dose, recommended phase 2 dose, dose-limiting toxicity, aggressive fibromatosis, thyroid cancer, pharmacokinetics, oral administration
- MeSH terms
- Administration, Oral, Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Enzyme Inhibitors, Female, Humans, Male, Middle Aged, Neoplasms, Tetrahydronaphthalenes, Valine, Treatment Outcome, Maximum Tolerated Dose, Amyloid Precursor Protein Secretases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-0607
- The paper
- Messersmith, W. A., Shapiro, G. I., Cleary, J. M., Jimeno, A., Dasari, A., Huang, B., Shaik, M. N., Cesari, R., Zheng, X., Reynolds, J. M., English, P. A., McLachlan, K. R., Kern, K. A., & LoRusso, P. M. (2015). A Phase I, Dose-Finding Study in Patients with Advanced Solid Malignancies of the Oral γ-Secretase Inhibitor PF-03084014. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-0607
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.